SEER icon

Seer Inc

1.67 USD
-0.02
1.18%
Updated Apr 1, 3:40 PM EDT
1 day
-1.18%
5 days
-8.24%
1 month
-18.93%
3 months
-28.33%
6 months
-13.92%
Year to date
-28.33%
1 year
-10.70%
5 years
-97.04%
10 years
-97.04%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

80% more call options, than puts

Call options by funds: $9K | Put options by funds: $5K

14% more capital invested

Capital invested by funds: $58.1M [Q3] → $66.5M (+$8.42M) [Q4]

0.96% more ownership

Funds ownership: 51.48% [Q3] → 52.43% (+0.96%) [Q4]

0% more funds holding

Funds holding: 70 [Q3] → 70 (+0) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

17% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 23

Research analyst outlook

We haven’t received any recent analyst ratings for SEER.

Financial journalist opinion

Based on 3 articles about SEER published over the past 30 days

Negative
Zacks Investment Research
1 week ago
After Plunging -16.59% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)
The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
After Plunging -16.59% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)
Negative
Zacks Investment Research
1 week ago
After Plunging -16.81% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)
Seer (SEER) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
After Plunging -16.81% in 4 Weeks, Here's Why the Trend Might Reverse for Seer (SEER)
Positive
Zacks Investment Research
3 weeks ago
Down -10.53% in 4 Weeks, Here's Why Seer (SEER) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Seer (SEER) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -10.53% in 4 Weeks, Here's Why Seer (SEER) Looks Ripe for a Turnaround
Neutral
Seeking Alpha
1 month ago
Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript
Seer, Inc. (NASDAQ:SEER ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of the Board David Horn - Chief Financial Officer and President Conference Call Participants Marta Zaremba - JPMorgan Jason Lai - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Seer Fourth Quarter and Full-Year 2024 Earnings Conference Call.
Seer, Inc. (SEER) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Seer, Inc. (SEER) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.28 per share a year ago.
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook
Neutral
GlobeNewsWire
1 month ago
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming TD Cowen 45th Annual Healthcare Conference in Boston, MA.
Seer to Participate in the TD Cowen 45th Annual Health Care Conference
Neutral
GlobeNewsWire
1 month ago
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer's Proteograph™ Product Suite Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer's Proteograph™ Product Suite
Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025
Neutral
GlobeNewsWire
1 month ago
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Seer to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Neutral
GlobeNewsWire
2 months ago
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
REDWOOD CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming J.P. Morgan 43rd Annual Healthcare Conference in San Francisco, CA.
Seer to Present at the J.P. Morgan 43rd Annual Healthcare Conference
Charts implemented using Lightweight Charts™